Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

By Robert Schreiber, Lloyd J. Old, M. Smyth. Science, 2011

6,056 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/9472a1d7da63597883db5e0f665a7c106ea84ac2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Guido Kroemer
2. M. Smyth
3. L. Galluzzi
4. L. Zitvogel
5. Lieping Chen
6. D. Pardoll
7. Oliver Kepp
8. S. Demaria

In Oncology

1. Guido Kroemer
2. Lieping Chen
3. D. Pardoll
4. L. Galluzzi
5. S. Demaria
6. S. Formenti
7. M. Smyth
8. L. Zitvogel

Citations in the corpus

• Inflammation and Cancer: Triggers, Mechanisms and Consequences (2019, background): “It has become clear now that the immune system can play significant pro- and anti-tumorigenic roles at all stages of the tumorigenesis (Koebel et al., 2007; McGranahan and Swanton, 2017; Rosenthal et al., 2019; Schreiber et al., 2011; Teng et al., 2008; Vesely et al., 2011; Zilionis et al., 2019).”
• Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
• Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. (2016, neutral): “This can occur via the surplus sources of immunosuppression in the tumor microenvironment (TME) (Joyce and Fearon, 2015) or through immunoediting (Matsushita et al., 2012; Schreiber et al., 2011), in which the immune system itself participates in the selection of immune-resistant cancer cell clones.”
• Immune escape mechanisms as a guide for cancer immunotherapy (2014, background): “In this process termed "cancer immunoediting," cancer clones evolve to avoid immune-mediated elimination by leukocytes that have antitumor properties (6).”
• Cancer immunotherapy: harnessing the immune system to battle cancer. (2015, background): “This dual role by which the immune system can suppress and/or promote cancer growth is termed cancer immunoediting and consists of three phases: elimination, equilibrium, and escape (3).”
• Non-small cell lung cancer: current treatment and future advances. (2016, background): “Some cancer cells share characteristics with healthy cells and thus the immune system cannot differentiate between the body’s normal and abnormal (cancer) cells (71).”
• Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. (2012, background): “have at least three different but related outcomes: elimination, equilibrium, and escape [10].”
• Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma (2014, background): “In addition, we also found that an elevated SII was associated with vascular invasion, early recurrence, and a larger tumor size, indicating a more aggressive phenotype (4, 33).”